WELCOME TO BARCELONA

13th PVRI Annual World Congress on Pulmonary Vascular Disease

Date // 31 January - 3 February 2019

The PVRI meeting is endorsed by the Spanish Biomedical Research Networking Centre on Respiratory Diseases (CIBERES).
Barcelona, like most cities around the Mediterranean basin, has a long history dating back to 5,000 BCE. As is the case for all ancient cities, legends abound. I favour the myth of its foundation to the Carthaginian general Hamilcar Barca, father of the celebrated Hannibal, since this would link Barcelona directly to the Phoenicians, the ancestors of the Lebanese, who dominated for a while the commerce of the Mediterranean Sea. Barcelona, like Berytus or Beirut, was a famous Roman city and, located at opposite sides of the Mediterranean, these two cities share a similar climate, common history, mixing of rich cultures, beautiful beaches, and multiple pre-historic and Roman artefacts in their undergrounds.

We hope that you will enjoy, aside from the outstanding science that this Congress will offer, the vibrancy of this Catalonia city with its abundance of art (do not miss the opportunity to visit la Sagrada Familia or Antoni Gaudí’s other multiple artistic creations), music (Palau de la Musica Catalana is one of my favourite musical architectural sites) and unique culinary offerings. In the spirit of this multicultural city, our PVRI members have come from all over Europe, North and South America, Asia, Australia, Africa, China, India and the Middle East.

We are greatly indebted to our Scientific Organising Committee, composed of Sébastien Bonnet, Anna Hemnes, Steeve Provencher, Soni Savai-Pullamsetti, Christophe Guignabert and Joan-Albert Barberà, for an outstanding scientific programme. Joan-Albert is of course our officially designated PVRI host, having the honour to greet us directly to his home town. Therefore, all concerns, requests, and other favours should obviously be directed to him!

We could not have organised this meeting without the skills of our amazing Canterbury crew (Georgie, Margaret and Aaron) under the leadership of our CEO Stephanie Barwick.

Last, but certainly not least, our heartfelt thanks go to our Events Manager, Andrea Rich, for her unique organisational skills.

Bienvenidos todos en Barcelona!

President’s Foreword...
"Thank you very much everyone. It was a very valuable Congress. Wish to see you next year".

Umit Yasar Sinan, Istanbul University Institute of Cardiology, Turkey

SINGAPORE 2018
Welcome to Barcelona 2019

Our Scientific Leaders

On behalf of the Scientific Organising Committee, we would like to welcome you to Barcelona for this Annual Congress.

This year’s venue is further promoted to encourage young talent participation, to further enrich our learning experience.

Several novel features are programmed this year with several debate sessions, abstract based oral sessions, oral presentations awards, rapid fire poster session and moderated poster discussion sessions, oral presentations awards, rapid fire poster session and rapid fire poster awards. All winners will be announced at the Gala Dinner.

We hope you enjoy your time with us.

Soni Savai-Pullamsetti

Dr Soni Savai-Pullamsetti is a Group Leader at the Max Planck Institute for Heart and Lung Research, Bad Nauheim, and an Associate Professor at the Department of Medicine, University of Giessen, Germany.

Dr Pullamsetti serves as a core leader in the Excellence Cluster for Cardio Pulmonary System (ECCPS) - a programme dedicated to research at the American Thoracic Society (ATS), German Heart Centre (DZHK), and a Taskforce member of the 6th World Symposium on Pulmonary Hypertension (WSPH).

Dr Pullamsetti is published in well-received scientific journals such as Nature Medicine, Science Translational Medicine, Journal of Clinical Investigation, American Journal of Respiratory and Critical Care Medicine, and Circulation. She serves as a reviewer for well-received scientific journals. Currently she is serving on the editorial boards of Scientific Reports and Pulmonary Circulation - the official international peer reviewed journal of the American Thoracic Society (ATS).

Dr Pullamsetti’s group contributed to the discovery of tyrosine kinases and phosphodiesterase IV involvement in the neoplastic nature of the remodeled/valvular vasculature of pulmonary hypertension and pulmonary fibrosis. She has studied these signaling pathways in great detail and explored their therapeutic potential for PH treatment successfully and forecasting therapeutic concepts from bench to bedside. Her research group is focused on the role of central downstream molecules, with a major focus on transcription factors and epigenetic mechanisms underlying pulmonary hypertension and pulmonary fibrosis, to develop novel therapeutic strategies to reverse these devastating lung diseases.

Anna Hennes

Anna Hennes is a transitional physician-scientist with a research focus on the role of altered insulin-mediated intracellular signalling in the pulmonary vasculature and its right ventricle.

Dr Hennes’ clinical research interests include the role of insulin resistance and metabolic syndrome in human pulmonary vascular disease, with a focus on genetic susceptibility to these conditions, and deep molecular phenotyping of pulmonary vascular disease.

Sebastian Bonnet

Pulmonary Hypertension Research Group, Canadian Institutes of Health Research (CIHR)

After having completed a doctorate degree in vascular biology in Alberta, Sebastian Bonnet (MD, PhD) completed a doctorate degree in vascular biology in Alberta, and pursued a post-doctoral fellowship at the University of California San Diego before starting a career as a professor at Université Laval and a researcher at the university’s Centre de Recherche en Santé (CRS) where he continues his research in the cardiovascular field.

Dr Bonnet was named Fellow of the American Heart Association and Director of the Canadian Research Chair in Pulmonary Hypertension. This title, considered as one of the greatest honours in the scientific community, is allotted to researchers whose research interests, creativity and exceptional competence in the advancement of fundamental and clinical research in the cardiovascular field.

The accomplishments of Dr Bonnet led to the discovery of mechanisms causing pulmonary hypertension, a fatal disease which affects mainly young adults. His team discovered two substances likely to treat this disease effectively. Dr Bonnet is a founder and director of the pulmonary hypertension research group. Since 2016, Dr Rianne Paulin’s Olivia Boucheret fundamental research, joined the group.

The group of Dr Bonnet utilizes multidisciplinary and translational approach from genes to population in order to study the molecular and cellular mechanisms involved in the development of the process of vascular remodeling. This work identifies the signature of the cytokines involved in the disease and the clinical management of individuals affected by PH. His new wealth identified new therapeutic targets such as Pim-3, miR-204, PARP-1 or BMD2L in PAH.

Steve Provencher

Professor of medicine, Laval University, Director, Pulmonary Hypertension Programme, Institut universitaire de cardiologie et de pneumologie de Québec.

Dr Provencher has performed a two-year post-doctoral fellowship in pulmonary hypertension in France. Since 2005, he has been director of the PH programme at Laval University. His main research interests are the exercise pathophysiology and mechanisms leading the pulmonary vascular remodeling in PH. Over his short career, Dr Provencher has published over 125 scientific papers and has been invited to speak at over 150 provincial, national or international congresses or symposiums.

In 2011, Dr Provencher also received the Prix reconnaissance Marc Julien, awarded by the International Medical societies in recognition of outstanding work done in teaching hospitals, dedication to his patients, clinical skills and quality of care.

Jean Barberà

University of Barcelona, Barcelona, Spain

Dr Joan Albert Barberà, MD is Chief of the Department of Pulmonary Medicine and Allergy at the Vall d’Hebron University Hospital, Barcelona, Associate Professor of Medicine at the University of Barcelona, and Fellow of the European Respiratory Society (ERS), United Kingdom.

He is the Director of the National Reference Unit on Rare Pulmonary Diseases at the Hospital Clinic of Barcelona, which belongs to the European Reference Network on Rare Pulmonary Diseases (ERN-LUNG). Furthermore, he is the Head of the Pulmonary Hypertension Programme, the Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), a network of excellence on respiratory research funded by the Carlos III Health Institute, Ministry of Health. He leads a translational research group devoted to the alterations in the pulmonary circulation associated with respiratory diseases, in particular chronic obstructive pulmonary disease.

Christophe Guignabert

Research Director (Associate professor) at INSERM UMR 927, Université Paris-Saclay, France

Dr Christophe Guignabert currently leads the Pulmonary endothelial dysfunction and cell cell communication in pulmonary arterial hypertension team, which focuses on the aberrant pulmonary endothelial cell phenotypes and on the identification of new molecular targets. His research seeks to better understand the role played by endothelial cells in the pulmonary vascular remodeling associated with PAH, and to identify key mechanisms by which pulmonary arterial cells interact with their environment (vascular smooth muscle cells, myofibroblasts, pericytes, and inflammatory cells).

His team has highlighted several major functional alterations in the pulmonary vascular endothelium in PAH:

• an activated state with adhesive capacity
• an aberrant pro-proliferative, apoptosis-resistant and pro-inflammatory phenotype
• an excessive production and secretion of several key soluble factors that contribute to the structural and functional pulmonary vascular remodeling.

More recently, he investigated the molecular mechanisms underlying the development of PH induced by intravenous agonists, and is assaying expert in in vitro experiments in primary human endothelial cells, in vitro models of experimental pulmonary hypertension.
“This meeting is a real success, with a perfect mix between basics and clinics. I am not a clinician and I appreciate having interactions with the clinics, giving deeper meaning to my research work. I look forward to attending the Washington summer meeting and to have also interactions with the pharma companies.”

Sylvia Cohen-Kaminsky, University Paris-Sud, France

SINGAPORE 2018
Scientific Meeting Thursday 31 January Morning Session // Lecture Programme (08:00-12:30)

08:00 - 08:10

Welcome

08:10 - 10:10

Plenary 1
Moderators:
Olivier Boucherat, Université Laval, Canada
Lan Zhao, Imperial College, UK

Adaptation to High Altitude - More than expected

08:10
Historical discovery of HPV and its physiological and pathophysiological importance // Jason Yu, University of California San Diego (UCSD), USA

08:20
Redox signaling in pulmonary circulation from HPV to pulmonary hypertension // Jeremy Ward, King’s College, UK

08:30
The role of vitamin D deficiency in PH // Francisco Perez-Vizcaino, University of Madrid, Spain

08:40
Mitochondria and oxygen sensing in pulmonary circulation // Stephen Archer, Queen’s University, Belfast, UK

09:00
Genetic adaptation to high altitude // Qadar Pasha, Institute of Genomics & Integrative Biology, India

Discussion

10:10 - 10:30

BREAK

Best abstract oral presentations (four basic & four clinical research)
Moderators:
Sébastien Bonnet, Université Laval, Canada
Anna Hemnes, Vanderbilt University, USA
Vinicio de Jesus Perez, Stanford University, USA
Kimio Satoh, Tohoku University School of Medicine, Japan
Gerald Simonneau, Hôpitaux Universitaires Paris Sud, France
Geoff Strange, Pulmonary Hypertension Society of Australia & New Zealand, Australia

Best abstracts presentation awards competition from our trainees.
10 minutes presentation and 5 minutes questions. 4 awards for the top 2 in each category.

10:30 - 12:30

Pulmonary Circulation Editorial Board Meeting
Held in // Diamant Room

12:30 - 13:30

LUNCH

12:30 - 13:30

Lunch
### Scientific Meeting Thursday 31 January Afternoon Session // Lecture Programme (13:30-20:30)

#### Event

**Plenary 2**

Moderators:
- Paul Hassounek, Johns Hopkins School of Medicine, USA
- Farid Rashidi, Tabriz University of Medical Sciences, Iran

**Systemic disorders in pulmonary hypertension**
- Non-coding RNA and skeletal muscle disorders in PAH and consequences on exercise tolerance // Steve Prouvost // Université Laval, Canada
- Senescent manifestations in COPD-PH // Serge Adnot // Institut National de Recherche Biomédicale, France
- PVDomics // Jane Leopold // Harvard University, USA
- Novel comorbidities in PAH patients // Roham Zamanian // Stanford University, USA

**Discussion**

**BREAK**

**14:30 - 14:45**

**Plenary 3**

Moderators:
- Harm-Jan Bogaard // University of Gießen, Germany
- Werner Seeger // Justus Liebig University of Gießen, Germany
- Adam Torbicki // Ecz-Otwock, Medical Centre for Post Graduate Education, Poland

**Pro and con debate: top issues and controversies in different groups of PH**
- Pulmonary vascular alterations are an important driver of COPD (PRO) // Norbert Weissman // Justus Liebig University of Gießen, Germany
- Pulmonary vascular alterations are an important driver of COPD (CON) // Ei-Iki Marukawa // National Hospital, Japan
- Targeting metabolic syndrome is a strategy to treat PH associated with left heart disease // HFpEF (PRO) // Charly Lai // Indiana University School of Medicine, USA
- Targeting metabolic syndrome is a strategy to treat PH associated with left heart disease // HFpEF (CON) // Valentina Mercurio // Federico II University, Italy
- Defective angiogenesis is a major contributor of CTEPH (PRO) // Rozenn Quarck // KU Leuven, Belgium
- Defective angiogenesis is a major contributor of CTEPH (CON) // Patricia Thistlethwaite // University of California, USA

**BREAK**

**16:45 - 17:00**

**Late-breaking oral clinical abstracts presentation**
- CMC Credits

**PVRI Annual General Meeting**

Held in // Verdi Room

**Welcome & Networking Reception**

Held in // Rossini, Terraza & Vivaldi Rooms

**END OF DAY ONE SCIENTIFIC SESSIONS**

---

**Bob Peterson, USA**

SINGAPORE 2018

---

**CME Credits**

This event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and is designed for a maximum of up to 23 European CME credits (ECMEC). Physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.
Glad we had breaks! Great location, good hotel, well organised poster sessions; lots of traffic and educational discussions.

Debbie Quinn, USA
SINGAPORE 2018

---

**Scientific Meeting Friday 1 February Morning Session // Lecture Programme (08:10-12:30)**

**Event**

### Plenary 4

**Moderators:**
- Roxane Paulin, Université Laval, Canada
- Frédéric Perros, INSERM UMR 909, Université Paris Saclay/France

**Epigenetics - from RV failure to pulmonary circulation: any therapeutic values?**

08:10 - 10:10

**PROFESSOR SHEILA GLENNIS HAWORTH LECTURE:**
Cellular heterogeneity, epigenetic regulation and metabolic transitions in cardiopulmonary development and disease // Thomas Tissot, Brafert Max Planck Institute for Heart and Lung Research, Germany

10 years of miRNAs research in PAH: any therapeutic values? // Stephen Chan, University of Pittsburgh, USA

Methylation acetylation disorders in PAH // Soni Savar-Pullamsetti, Max Planck Institute for Heart and Lung Research, Germany

**RUPERT SWIFT LECTURE:**
Methylation and miRNAs in RV failure // François Potus, Queen's University, Canada

**Discussion**

---

**Break**

08:10 - 10:30

---

### Plenary 5

**Moderators:**
- Hua Luo, Peking University Shenzhen Hospital, China
- Yuri Sirenko, Strazhesko Institute of Cardiology, Ukraine
- Yuichi Tamura, International University of Health & Welfare, Japan
- Jason Weatherald, University of Calgary, Canada

**What have we learned from national PH registries?**

What have we learned from the existing PAH registries? // Marc Humbert, Hôpitaux Universitaires, Paris-Sud, France

What have we learned from the existing PAH registries? // Marc Humbert, Hôpitaux Universitaires, Paris-Sud, France

What have we learned from the existing PAH registries? // Marc Humbert, Hôpitaux Universitaires, Paris-Sud, France

What have we learned from the existing PAH registries? // Marc Humbert, Hôpitaux Universitaires, Paris-Sud, France

What have we learned from the existing PAH registries? // Marc Humbert, Hôpitaux Universitaires, Paris-Sud, France

**Registries beyond PAH: what are the existing registries and where are the knowledge gaps?** // Marc Humbert, Hôpitaux Universitaires, Paris-Sud, France

Pitfalls in interpreting cohort and registry data // Geoff Strange, Pulmonary Hypertension Society of Australia & New Zealand, Australia

Establishing registries in the developing world // Abdullah al-Dalaan, King Faisal Specialist Hospital & Research Centre, Saudi Arabia

Paediatric registries // Maria Jesus del Carmen Martinez, Ramón y Cajal University Hospital, Spain

**Discussion**
**Overall, a very well composed and insightful conference. Excellent conference to meet and talk to so many researchers**.

Christina Eichstaedt, Germany
**SINGAPORE 2018**

---

### Scientific Meeting Friday 1 February Afternoon Session // Lecture Programme (12:30-18:00)

**Held In** // Verdi Room

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plenary 6</strong></td>
<td>12:30 - 12:55</td>
</tr>
<tr>
<td>Moderators:</td>
<td></td>
</tr>
<tr>
<td>// Stephen Archer QUEEN'S UNIVERSITY, CANADA</td>
<td></td>
</tr>
<tr>
<td>// Soni Savai-Pullamsetti MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH, GERMANY</td>
<td></td>
</tr>
<tr>
<td><strong>Rapid fire oral presentation award session for basic science</strong></td>
<td></td>
</tr>
<tr>
<td>3 minutes presentation and 2 minutes questions. 2 awards for the top 2.</td>
<td></td>
</tr>
<tr>
<td><strong>Meet the Editors of Pulmonary Circulation</strong> Held in // Verdi Room</td>
<td>13:00 - 14:00</td>
</tr>
</tbody>
</table>

**Paediatric & Congenital Heart Disease Task Force Meeting** Held In // Diamant Room

**Chairs:**
- Steven Abman UNIVERSITY OF COLORADO DENVER SCHOOL OF MEDICINE, USA
- Maria Jesus del Corral RAMON Y CAJAL UNIVERSITY HOSPITAL, SPAIN
- Shahin Molokned Great Ormond Street Hospital, UK

**13:00 - 19:45**

**Innovative Drug Development Initiative Working Group Meeting** Held In // Cristal & Coral Rooms

**Chairs:**
- Paul Corris NEWCASTLE UNIVERSITY, UK
- Peter Fernandes BELLEROPHON THERAPEUTICS, USA
- Sylvia Nikkho BAYER, GERMANY

14:00 - 18:00

---

We thank all our pharma companies for their sponsorship and contributions.

---

**CME Credits**
This event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and is designed for a maximum of or up to 23 European CME credits (ECMEC). Physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.
## Scientific Meeting Saturday 2 February Morning Session // Lecture Programme (08:10 - 12:30)

**Event**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:10 - 10:10</td>
<td><strong>Plenary 7</strong>&lt;br&gt;<strong>Moderators:</strong>&lt;br&gt; Allan Lawrie, UNIVERSITY OF SHEFFIELD, UK&lt;br&gt; Olga Tura, IDIBAPS, SPAIN&lt;br&gt; <strong>Metabolic disorders: tomorrow's heart failure and PAH therapeutic targets?</strong></td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>10:30 - 12:30</td>
<td><strong>Plenary 8</strong>&lt;br&gt;<strong>Moderators:</strong>&lt;br&gt; Marc Humbert, HÔPITAUX UNIVERSITAIRES, PARIS-SUD, FRANCE&lt;br&gt; Steeve Provencher, UNIVERSITÉ LAVAL, CANADA&lt;br&gt; <strong>New definitions and interpretations of haemodynamic data</strong></td>
</tr>
</tbody>
</table>

### Plenary 7: Metabolic disorders: tomorrow’s heart failure and PAH therapeutic targets?

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:10 - 10:10</td>
<td><strong>Plenary 7</strong>&lt;br&gt;<strong>Moderators:</strong>&lt;br&gt; Allan Lawrie, UNIVERSITY OF SHEFFIELD, UK&lt;br&gt; Olga Tura, IDIBAPS, SPAIN&lt;br&gt; <strong>Metabolic disorders: tomorrow's heart failure and PAH therapeutic targets?</strong></td>
</tr>
</tbody>
</table>

**PROFESSOR STUART RICH LECTURE:** Potential usefulness of sound wave therapies for circulatory disorders - From angina to dementia<br> Hiroaki Shimokawa, TOHOKU UNIVERSITY, JAPAN

**Pim2 and heart failure: what can we learn from that?**<br> Gopinath Sutendra, UNIVERSITY OF ALBERTA, CANADA

**AMPK and PAH**<br> Mark Evans, UNIVERSITY OF EDINBURGH, UK

**Mitochondrial dysfunction in PAH**<br> Nubuhito-kituchi, TOHOKU UNIVERSITY, JAPAN

**The breath volatolome as a snapshot of body metabolism: Not to be neglected in PAH**<br> Sylvia Cohen-Kaminsky, INSEEM-LAM, SPP, UNIVERSITÉS PARIS-Saclay, FRANCE

**Metabolic modulators and PAH clinical trials: from DCA to Ranolazine**<br> Evangelos Michelakis, UNIVERSITY OF ALBERTA, CANADA

**Discussion**

**BREAK**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 - 10:30</td>
<td><strong>BREAK</strong></td>
</tr>
</tbody>
</table>

**Plenary 8: New definitions and interpretations of haemodynamic data**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:30</td>
<td><strong>Plenary 8</strong>&lt;br&gt;<strong>Moderators:</strong>&lt;br&gt; Marc Humbert, HÔPITAUX UNIVERSITAIRES, PARIS-SUD, FRANCE&lt;br&gt; Steeve Provencher, UNIVERSITÉ LAVAL, CANADA&lt;br&gt; <strong>New definitions and interpretations of haemodynamic data</strong></td>
</tr>
</tbody>
</table>

**Normal PAP in healthy subjects and beyond**<br> Gabor Kovacs, MEDICAL UNIVERSITY OF GRAZ, AUSTRIA

**What is the impact of mild PAP elevation?**<br> Robert Naeije, UNIVERSITÉ Libre de Bruxelles, BELGIUM

**PROs and CONs of the novel definition of PH**<br> Ryan Tedford, MEDICAL UNIVERSITY OF SOUTH CAROLINA, USA

**PAWP versus LVEDP: does it really matter?**<br> Ryan Tedford, MEDICAL UNIVERSITY OF SOUTH CAROLINA, USA

**PAH with marginal PAWP: a different disease, different phenotype or a misclassification?**<br> Evan Brittain, VANDERBILT UNIVERSITY, USA

**Discussion**

**LUNCH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 - 13:30</td>
<td><strong>LUNCH</strong></td>
</tr>
</tbody>
</table>
### Scientific Meeting

**Saturday 2 February Afternoon Session // Lecture Programme (13:30-19:30)**

#### Plenary 9

**Moderators:** Michele Aldred, **Indian University, USA** // Ralph Schermuly, **Justus Liebig University of Gießen, Germany**

- **Plenary cells in PH: good, bad and reformable**
  - Pericytes in PAH // Vinicio J. Joffre, Stanford University, USA
  - The impact of BMPR2 loss on endothelial-immune interactions in PAH // Mark Omriston, Queen’s University, Canada
  - Role of circulating progenitors in pulmonary vascular repair and remodelling // Duncan Stewart, Ottawa Hospital Research Institute, Canada
  - Resident progenitors contribute to pulmonary vascular remodelling // Daniel Greif, Yale University, USA
  - Exosomes – outlook for future cell-free PH therapy? // James Scally, Indiana University, USA

**Discussion**

**Time:** 13:30 - 15:30

#### Plenary 10

**Moderators:** Joan Albert Barbera, **Hospital Clinic of Barcelona, Spain** // Reda Girgis, **Spectrum Health, USA**

- **Rapid fire oral presentation award session clinical research**
  - 3 minutes presentation and 2 minutes questions. 2 awards for the top 2.

**Time:** 15:50 - 16:15

#### Plenary 11

**Moderators:** Joe GN ‘Skip’ Garcia, **University of Arizona, USA** // Evangelos Michelakis, **University of Alberta, Canada**

- **From preclinical studies to drug approval in PAH: a long unpaved road**
  - The industry overview of clinical development for novel targets in PAH: Considerations and expectations before initiating early-stage clinical programmes // Michael Callahan, Harvard Medical School USA
  - Repurposing drugs for an orphan disease: opportunities and pitfalls // Edita Furdik, **Spectrum Health**, USA
  - The landscape of clinical trials has changed in PAH: stakeholder’s are raising the bar // Josep Torrent-Farnell, Autonomous University of Barcelona, Spain
  - Choosing the best of the best: How do we select the most promising drugs for trials in human pulmonary hypertension? // Ardeschir Ghofrani, Justus Liebig University of Gießen, Germany
  - Future clinical trials in PAH: what innovative strategies will be needed to succeed? // Frances de Man, VU University, Netherlands
  - The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: Results from a national survey // Zhenguo Zhai, China-Japan Friendship Hospital, China

**Time:** 16:35 - 18:15

#### Moderated Poster Session

**Time:** 18:15 - 19:30

---

**PVRI GALA DINNER** (All welcome, including partners & guests)

Buy your ticket at the Reception Desk

**Time:** 20:00 onwards

---

**Scientific Meeting // PVRI **

**Saturday 2 February**

---

**CME Credits**

This event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and is designed for a maximum of, or up to **23 European CME credits (ECMEC)**. Physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.
Plenary 12

Moderators:
// Hiroshi Matsubara
DEPARTMENT OF CARDIOLOGY, OKAYAMA MEDICAL CENTER, JAPAN
// Farid Rashidi
TAHRIZ UNIVERSITY OF MEDICAL SCIENCES, IRAN

The changing landscape of treatment armament: is standard of care in pulmonary hypertension still debatable?

Initial double combination therapy is now standard of care for PAH // Olivier Sitbon
HÔPITAUX UNIVERSITAIRES, PARIS-SUD, FRANCE

Rapid goal-oriented sequential therapy remains the standard for most non-high-risk PAH patients // Richard Cannick
PULMONARY & CRITICAL CARE MEDICINE, MASSACHUSETTS GENERAL HOSPITAL, USA

BPA is now the treatment of choice in e-TEPH patients with non-surgically accessible disease // David Poch
UNIVERSITY OF SAN DIEGO, USA

BPA should be reserved for inoperable CTEPH refractory to medical therapy // Joanna Pepke-Zaba
PAPWORTH HOSPITAL NHS FOUNDATION TRUST, UK

Discussion

B R EAK

10:10 - 10:30

Plenary 13

Moderators:
// Stefano Ghio
POLICLINICO SAN MATTEO PAVIA FONDAZIONE ERCI, ITALY
// Anna Hemnes
VANDERBILT UNIVERSITY, USA

Early screening in patients at risk of PAH: Are we doing enough? Are we doing too much?

Systematic annual screening of all scleroderma patients with PFTs, imaging and circulating biomarkers is mandatory // Stephen Mathai
JOHNS HOPKINS SCHOOL OF MEDICINE, USA

Stress echo/haemodynamics identifies a subgroup of patients with pulmonary vascular disease that should be treated // Rebecca Vanderpool
UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE, USA

Stress echo/haemodynamics most commonly identifies left heart dysfunction and has poor specificity for pulmonary vascular disease // Jean-Luc Vachiery
HOPITAL ERASMUS, UNIVERSITY OF BRUSSELS, BELGIUM

Screening of pulmonary arterial hypertension in BMP12 mutation carriers // David Mattos
HOSPITAL BICÊTRE, UNIVERSITY OF PARIS-SUD, FRANCE

Discussion

END OF CONGRESS

PVRI Digital Clinic e-learning Phase 2: patient cases discussion

Held in: Tenerife Room

14:00 - 16:00
"The conference was very good and I’m very honoured to be invited and to participate."
Andrea D’Armini, Italy
SINGAPORE 2018

Gala Dinner

Please join us at our Gala Dinner on Saturday 2 February 2019 at 20:00, which is being held at Ultramarinos Restaurant, with live entertainment.
Tickets are available at the Reception Desk.

Our Gala Dinner Evening
Congratulations on the achievements of all our members throughout 2018...

Our Gala Dinner is always a wonderful occasion where we celebrate the achievements of our members. This year, we will present the following awards:

- PVRI Achievement Awards 2018
- PVRI Certificates of Excellence 2018
- Rupert Swift Award 2018
- The Butrous Foundation Young Investigator Award 2018

I invite you all to attend our Gala Dinner. It promises to be a lively evening!

We congratulate all of our winners and are extremely proud of their achievements.

Butrous Foundation Young Investigator Award

The Butrous Foundation Young Investigator Award is presented to a young investigator at the annual PVRI World Congress. The Butrous Foundation is a private foundation established in 2006, which aims to motivate young people to pursue scientific careers by enhancing scientific creativity and communication skills. It also provides a platform for young people all over the world to participate in scientific advancements and to encourage them to express their ideas freely and creatively.

The Award provides $500 to one young investigator and an additional $500 to publish their research in Pulmonary Circulation, subject to the normal peer-review process.

For further information and to find the criteria for eligibility, please visit the website: www.butrousfoundation.com

Stephanie Barwick
Chief Executive Officer
Canterbury, UK

“Very good selection of various topics. Extremely useful pre-meetings, quite informal atmosphere and excellent discussions. Good balance between the basic and clinical science and very useful discussions during the session, probably due to relatively small size of the conference and the absence of parallel sessions, so almost all the people could be present and contribute...”

Olena Rudyk, United Kingdom
SINGAPORE 2018
Our Speakers, Chairs & Contributors continued...

Stefano Ghio
Policlinico San Matteo
Pavia Fondazione IRCC, Italy

Andescir Ghofrani
Justus Liebig University of Giessen,
Germany

Reda Girgis
Spectrum Health, USA

Daniel Greif
Yale University, USA

Elena Goucharova
Division of Pulmonary, Allergic and Critical Care Medicine, Pittsburgh, USA

Christophe Gugnault
Research Director (Associate professor) at INSERM U1090, Université Paris-Saclay, France

Paul Hansson
Johns Hopkins University School of Medicine, USA

Anna Hemnes
Vanderbilt University School of Medicine, USA

Marc Humbert
Hôpitaux Universitaires de Genève, Switzerland

Harry Karmy-Jones
Magee-Womens Hospital of UPMC, USA

Nobuhito Kikuchi
Tokyo University Graduate School of Medicine, Japan

James Kilgore
Brown University, USA

Gabor Kovacs
Medical University of Vienna, Austria

Tim Lahm
Indiana University School of Medicine, USA

Charly Lai
Indiana University School of Medicine, USA

Allan Lawrie
University of Sheffield, UK

Ghassan Latif
University of Houston, Houston, TX

Mark Long
Brigham and Women’s Hospital, Harvard Medical School, USA

Hiromi Matsubara
National Hospital Organization Ohashi Medical Center, Japan

Valentia Marra
Department of Translational Medical Sciences, Federico University at Naples, Italy

David Montani
Hopitaux Universitaires, Paris-Saclay, France

Marc Humbert
Hôpitaux Universitaires de Genève, Switzerland

Harry Karmy-Jones
Magee-Womens Hospital of UPMC, USA

Nobuhito Kikuchi
Tokyo University Graduate School of Medicine, Japan

James Kilgore
Brown University, USA

Gabor Kovacs
Medical University of Vienna, Austria

Tim Lahm
Indiana University School of Medicine, USA

Charly Lai
Indiana University School of Medicine, USA

Allan Lawrie
University of Sheffield, UK

Ghassan Latif
University of Houston, Houston, TX

Mark Long
Brigham and Women’s Hospital, Harvard Medical School, USA

Hiromi Matsubara
National Hospital Organization Ohashi Medical Center, Japan

Valentia Marra
Department of Translational Medical Sciences, Federico University at Naples, Italy

David Montani
Hopitaux Universitaires, Paris-Saclay, France
Our Speakers, Chairs & Contributors continued...

LISTED IN ALPHABETICAL ORDER

Geoff Strange
• Pulmonary Hypertension Society of Australia & New Zealand, Australia

Gopinath Sutendra
• University of Alberta, Canada

Patricia Thistlethwaite
• University of California, San Diego, USA

Thomas Thum
• Bonn University Medical School, Germany

Chiara Tura
• DIBAPS, August Pi i Sunyer Biomedical Research Institute, Spain

Jean-Luc Vachiery
• Erasme University Hospital, Brussels, Belgium

Rebecca Vandervoorst
• University of Arizona College of Medicine, Tucson, USA

Jeremy Ward
• King’s College London, UK

Jason Weatherald
• University of Calgary, Canada

Norbert Wiedermann
• Justus Liebig University of Giessen, Germany

Paul Williams
• Centre for Chest Disease & Critical Care, South Africa

Binta Wojcik-Stothard
• Imperial College London, UK

Jason Yuan
• University of California, San Diego (UCSD), USA

Roham Zamanian
• Stanford University, USA

Zhenguo Zhai
• China-Japan Friendship Hospital, China

Lan Zhao
• Imperial College, UK

Beata Wojciak-Stothard
• Imperial College London, UK

Yuichi Tamura
• International University of Health & Welfare, Japan

Ryan Tedford
• Medical University of South Carolina, USA

Adam Torbild
• GCS-Otwock/Med Centre for Postgraduate Education, Warsaw, Poland

Josep Torronto-Farnell
• Autonomous University of Barcelona, Spain

Joan Torreblanca
• University of California, San Diego, USA

Patricia Thistlethwaite
• University of California, San Diego, USA

Thomas Thum
• Bonn University Medical School, Germany

Chiara Tura
• DIBAPS, August Pi i Sunyer Biomedical Research Institute, Spain

Jean-Luc Vachiery
• Erasme University Hospital, Brussels, Belgium

Rebecca Vandervoorst
• University of Arizona College of Medicine, Tucson, USA

Jeremy Ward
• King’s College London, UK

Jason Weatherald
• University of Calgary, Canada

Norbert Wiedermann
• Justus Liebig University of Giessen, Germany

Paul Williams
• Centre for Chest Disease & Critical Care, South Africa

Binta Wojcik-Stothard
• Imperial College London, UK

Jason Yuan
• University of California, San Diego (UCSD), USA

Roham Zamanian
• Stanford University, USA

Zhenguo Zhai
• China-Japan Friendship Hospital, China

Lan Zhao
• Imperial College, UK

Beata Wojciak-Stothard
• Imperial College London, UK
During the latter part of 2018, the PVRI Digital Clinic was successful in obtaining additional funding to carry the project into Phase 2. Our aim is to combine feedback from Phase 1 and newly identified improvements to produce a platform that will become an evolving learning tool that retains its relevance in the ever-changing world of PH. PVRI members can view the course in its current form on the PVRI website, under the E-Learning tab.

Our ambition is to house 12 patient cases within the clinic, with the help of shortlisted leading PH centres around the world. These will be peer-reviewed by the PVRI Digital Clinic Committee, who will also announce calls for new cases.

We are sincerely grateful to our funding partners, Merck & Co and GSK for their support.

Martin Johnson
Digital Clinic Content Manager,
Glasgow, UK

Colin Church
Digital Clinic Content Manager,
Glasgow, UK

Aaron Shefras
Marketing Manager,
Canterbury, UK

The first scientific meeting of the International Consortium for Genetic Studies in PAH (PAH-ICON http://www.pahicon.com), sponsored by the PVRI, will immediately follow the PVRI 13th Annual World Congress. The meeting will include presentations and abstracts from researchers in the field of PAH genetics, and will provide an opportunity for collaborative networking and participating in future international collaborations in this rapidly evolving field.
Our Co-Chairs invite you to the PVRI 6th Annual Drug Discovery & Development Symposium in Paris

Date 1-2 July / Paris 2019
Hotel / Le Meridien Etoile - Paris

The official journal of the PVRI, Pulmonary Circulation is a leading forum for communication in the fields of pulmonary circulation and pulmonary vascular disease.

With a focus on translational science, the journal connects researchers and physicians in all parts of the world. An Open Access journal, articles are freely available to read immediately on publication. The journal’s goal is to advance our understanding of physiology and disease mechanisms pertaining to the pulmonary circulation and right heart, and to become the journal of choice for researchers in this field of science.

The Editors welcome article submissions including clinical and basic research in humans and animals, randomised controlled trials, intervention studies, and outcome studies. Articles published in Pulmonary Circulation will make a major impact not only on future research but also on improvement of health outcomes in our field.

Why publish in Pulmonary Circulation?
- Fast turnaround times.
- Articles posted online within 48 hours of acceptance and deposited in PubMed.
- 20-day target from submission to first decision.
- Immediate dissemination of articles to 6,000 PVRI members and affiliates, the global population of leading scientists and physicians studying the pulmonary circulation and pulmonary vascular disease.
- Article-level metrics for real-time updates on when your article has been read, cited or shared.
- Articles published Open Access allowing immediate access to all readers.
- Impact Factor 2.283.

Call for Article Submissions

Pulmonary Circulation
Editors in Chief: Jason X.-J. Yuan MD, San Diego, USA & Nicholas W. Morrell MD, Cambridge, UK
Deputy Editor: Kurt R. Stenmark MD, Denver, USA & Irene Lang MD, Vienna, Austria
Our Belief

Why do we exist?
We exist to facilitate collaboration between the world’s leading pulmonary vascular professionals to push the boundaries of what’s possible in medicine.

Our thinking
Our members actively inspire each other. Adhering to our values and celebrating our community will always be essential to our progress.

Our values
We value integrity and independence. Strengthening collaboration and friendships that exist within the organisation maintains this connection as we grow.

Our members
Our members range from actively participating post-doctoral students to the world’s leading scientists and clinicians. This holistic perspective is unique to us as an organisation and one we are most proud of.

What does collaboration mean to us?
Collaboration is the recognition of trust in each other’s knowledge, skills and commitment to our community.
Today’s work... tomorrow’s possibility.